|
|
|
|
||
Re: Historical development; BVTI relationsAccentia cancer vaccine gets positive review Tampa Bay Business Journal Date: Thursday, April 17, 2008, 2:16pm EDT - Last Modified: Thursday, April 17, 2008, 2:16pm EDT Sponsored Links Get Listed Here BiovaxID, a proposed treatment for non-Hodgkin's lymphoma being developed by a subsidiary of Accentia Biopharmaceuticals Inc., has gotten an endorsement from a key review panel. The Independent Data Monitoring Committee, which is vested with the responsibility of monitoring the safety and efficacy of Phase 3 clinical trials for BiovaxID, recommended moving forward with a process to get the drug to market, according to a release from Accentia. The committee completed a closed session review of results from the Phase 3 study and volunteered to participate, if needed, in ongoing regulatory meetings with the U.S. Food and Drug Administration and with other regulatory agencies worldwide in order to determine the most appropriate process for unblinding the results and establishing a pathway to seek marketing approvals, the release said. BiovaxID is being developed by Biovest International Inc. (OTCBB: BVTI), a subsidiary in which Accentia holds a 76 percent ownership stake. Accentia also maintains a 19.5 percent royalty interest in global sales of BiovaxID. After release of the news, shares of Accentia (NASDAQ: ABPI), a biopharmaceutical company based in Tampa, were trading at $1.44 a share at mid-day Thursday, up more than 75 percent over Wednesday's close. Separately, Accentia announced the resignation of John Dubinsky, a member of the board of directors since Accentia went public in October 2005. Dubinsky, chief executive of Westmoreland Associates LLC, a financial consulting firm in St. Louis, resigned because of other business and personal commitments and not as a result of any disagreement with Accentia, according to a filing with the Securities and Exchange Commission. Dr. Christopher Chapman, former executive vice president of medical and regulatory affairs and director of new business development for BioDelivery Sciences International Inc. (NASDAQ: BDSI), was appointed to the Accentia board. Follow Your Favorites with My News My News is a way to create a customi |
return to message board, top of board |